ImmuPharma (LON:IMM) Trading 28.6% Higher - Still a Buy?

Key Points

• ImmuPharma's share price surged by 28.6% during mid-day trading, reaching a high of GBX 12 ($0.16), with a trading volume increase of 97% from average session volumes.
• The company's market capitalization is £56.47 million, and it reported a negative earnings per share (EPS) of GBX (0.38) for the last quarter.
• ImmuPharma focuses on developing peptide-based therapeutics, including Lupuzor™, designed to treat autoimmune diseases like Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price traded up 28.6% during mid-day trading on Tuesday . The stock traded as high as GBX 12 ($0.16) and last traded at GBX 11.30 ($0.15). 17,007,168 shares traded hands during trading, an increase of 97% from the average session volume of 8,614,648 shares. The stock had previously closed at GBX 8.79 ($0.12).

ImmuPharma Stock Performance

The company has a market capitalization of £56.47 million, a P/E ratio of -1,269.66 and a beta of 1.53. The firm's fifty day moving average is GBX 5.30 and its 200-day moving average is GBX 3.58.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.